Renovorx reports second quarter 2023 financial results and operational highlights

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended june 30, 2023. “we made strong progress this quarter and have continued momentum in our commitment to transform the lives of patients by delivering innovative solutions to change the current paradigm of cancer care,” said shaun bagai, ceo of renovorx. “.
RNXT Ratings Summary
RNXT Quant Ranking